Approved Research

SafePolyMed: Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions (https://www.safepolymed.eu/)

Lay summary

The main objectives of SafePolyMed are:

 To increase patient safety and equip health care HC providers with innovative tools for tackling future challenges of our health systems via the development of a novel, evidence-based risk

scoring system using machine learning (ML) on large real-world datasets to identify patients at risk considering polypharmacy, multimorbidity, genetic variations as well as demographic and

disease related factors.

To increase citizen participation and resilience in HC via the identification and validation of patient reported outcome measures (PROMs) for multifactorial patient safety and a patient engagement hub including training in close collaboration with European patient organisations.

To empower patients/citizens to proactively manage their own HC by equitably accessible health relevant information via the development of a digital, citizen-centred medication management center (MMC) serving as comprehensive, sustainable knowledge hub in Europe.

 To increase patient safety towards personalised treatment plans in complex pharmacotherapeutic situations via the establishment of a model library of clinically relevant compounds to derive individualised precision dose adaptations for safe and effective dose regimens in case of DDGIs with the help of physiologically based pharmacokinetic (PBPK) modelling techniques.

 To support development and uptake of innovative HC services in Europe via the validation of the in SafePolyMed developed HC tools in a clinical case study, serving as a "proof-of-principle" including representative patients from different clinical sites from different European countries, and providing a blueprint of such participative trials in polymedication.

The project duration will last for 42 months and the start date is 01 June 2022.

The SafePolyMed team will contribute to establishing sustainable infrastructures that help foster patient involvement and bolster exchange with patient organisations to increase participation in healthcare and empower citizens and patients to take on a more active role in their own therapy management.